Alcon, the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof IQ Vivity and Clareon Vivity extended depth of focus (EDOF) intraocular lens (IOL) has surpassed more than one million implants worldwide. Vivity is the most implanted EDOF IOL globally.
Alcon’s Investigational Drops Show Promising Phase III Data in Dry Eye Disease
Alcon Canada Launches Clareon Vivity
Alcon Showcases Cloud-based Planning and World-class Digital Technologies During AAO 2023
Thousands of company associates across 30 countries participate in the initiative that inspires associates to make direct, positive impacts in their local communities
Alcon Reports First Quarter 2023 Results
FORT WORTH, Texas--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will once again have the largest surgical ophthalmic presence at the American Society of Cataract and Refractive Surgery (ASCRS) 2023 Annual Meeting, taking place May 5-8 in San Diego. The company is proud to have the benefits of its innovations featured in more studies than ever in its history.1 Alcon will showcase product updates that drive efficiencies for ophthalmologists and staff, and host events with surgeons sharing their real-world experiences. Alcon ASCRS event information and registration is available at MyAlconatASCRS.com.
Alcon to Host 2023 Capital Markets Day
When Alcon eye care spun out of Novartis as an independent company, the ophthalmology pharmaceuticals business stayed at the Big Pharma. For Alcon, though, it was an “obvious” gap in its eye care and eye health expertise, so it went out and began acquiring and building out a prescription eye drug portfolio.
Alcon Reports Fourth Quarter and Full Year 2022 Results